365 related articles for article (PubMed ID: 34336822)
1. Genetic Imaging of Neuroinflammation in Parkinson's Disease: Recent Advancements.
Yao L; Wu J; Koc S; Lu G
Front Cell Dev Biol; 2021; 9():655819. PubMed ID: 34336822
[TBL] [Abstract][Full Text] [Related]
2. Glutathione
Jewett M; Dickson E; Brolin K; Negrini M; Jimenez-Ferrer I; Swanberg M
Front Neurol; 2018; 9():222. PubMed ID: 29681884
[TBL] [Abstract][Full Text] [Related]
3. Genetics of Parkinson's disease: a review of SNCA and LRRK2.
Konno T; Siuda J; Wszolek ZK
Wiad Lek; 2016; 69(3 Pt 1):328-32. PubMed ID: 27486710
[TBL] [Abstract][Full Text] [Related]
4. Neuroinflammation in Parkinson's Disease and its Treatment Opportunities.
Çınar E; Tel BC; Şahin G
Balkan Med J; 2022 Sep; 39(5):318-333. PubMed ID: 36036436
[TBL] [Abstract][Full Text] [Related]
5. Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention.
Tansey MG; Goldberg MS
Neurobiol Dis; 2010 Mar; 37(3):510-8. PubMed ID: 19913097
[TBL] [Abstract][Full Text] [Related]
6. Genetic Defects and Pro-inflammatory Cytokines in Parkinson's Disease.
Magnusen AF; Hatton SL; Rani R; Pandey MK
Front Neurol; 2021; 12():636139. PubMed ID: 34239490
[TBL] [Abstract][Full Text] [Related]
7. Protein kinase Cδ upregulation in microglia drives neuroinflammatory responses and dopaminergic neurodegeneration in experimental models of Parkinson's disease.
Gordon R; Singh N; Lawana V; Ghosh A; Harischandra DS; Jin H; Hogan C; Sarkar S; Rokad D; Panicker N; Anantharam V; Kanthasamy AG; Kanthasamy A
Neurobiol Dis; 2016 Sep; 93():96-114. PubMed ID: 27151770
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the JAK/STAT Pathway Protects Against α-Synuclein-Induced Neuroinflammation and Dopaminergic Neurodegeneration.
Qin H; Buckley JA; Li X; Liu Y; Fox TH; Meares GP; Yu H; Yan Z; Harms AS; Li Y; Standaert DG; Benveniste EN
J Neurosci; 2016 May; 36(18):5144-59. PubMed ID: 27147665
[TBL] [Abstract][Full Text] [Related]
9. Back and to the Future: From Neurotoxin-Induced to Human Parkinson's Disease Models.
Airavaara M; Parkkinen I; Konovalova J; Albert K; Chmielarz P; Domanskyi A
Curr Protoc Neurosci; 2020 Mar; 91(1):e88. PubMed ID: 32049438
[TBL] [Abstract][Full Text] [Related]
10. HCH6-1, an antagonist of formyl peptide receptor-1, exerts anti-neuroinflammatory and neuroprotective effects in cellular and animal models of Parkinson's disease.
Wang HL; Cheng YC; Yeh TH; Liu HF; Weng YH; Chen RS; Chen YC; Lu JC; Hwang TL; Wei KC; Liu YC; Wang YT; Hsu CC; Chiu TJ; Chiu CC
Biochem Pharmacol; 2023 Jun; 212():115524. PubMed ID: 37001680
[TBL] [Abstract][Full Text] [Related]
11. Inflammasome inhibition protects dopaminergic neurons from α-synuclein pathology in a model of progressive Parkinson's disease.
Grotemeyer A; Fischer JF; Koprich JB; Brotchie JM; Blum R; Volkmann J; Ip CW
J Neuroinflammation; 2023 Mar; 20(1):79. PubMed ID: 36945016
[TBL] [Abstract][Full Text] [Related]
12. p38-TFEB pathways promote microglia activation through inhibiting CMA-mediated NLRP3 degradation in Parkinson's disease.
Chen J; Mao K; Yu H; Wen Y; She H; Zhang H; Liu L; Li M; Li W; Zou F
J Neuroinflammation; 2021 Dec; 18(1):295. PubMed ID: 34930303
[TBL] [Abstract][Full Text] [Related]
13. MPTP-driven NLRP3 inflammasome activation in microglia plays a central role in dopaminergic neurodegeneration.
Lee E; Hwang I; Park S; Hong S; Hwang B; Cho Y; Son J; Yu JW
Cell Death Differ; 2019 Jan; 26(2):213-228. PubMed ID: 29786072
[TBL] [Abstract][Full Text] [Related]
14. The role of tyrosine hydroxylase-dopamine pathway in Parkinson's disease pathogenesis.
Zhou ZD; Saw WT; Ho PGH; Zhang ZW; Zeng L; Chang YY; Sun AXY; Ma DR; Wang HY; Zhou L; Lim KL; Tan EK
Cell Mol Life Sci; 2022 Nov; 79(12):599. PubMed ID: 36409355
[TBL] [Abstract][Full Text] [Related]
15. Neuron-Astrocyte Interactions in Parkinson's Disease.
Miyazaki I; Asanuma M
Cells; 2020 Dec; 9(12):. PubMed ID: 33297340
[TBL] [Abstract][Full Text] [Related]
16. Surprising behavioral and neurochemical enhancements in mice with combined mutations linked to Parkinson's disease.
Hennis MR; Marvin MA; Taylor CM; Goldberg MS
Neurobiol Dis; 2014 Feb; 62():113-23. PubMed ID: 24075852
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-124 regulates the expression of MEKK3 in the inflammatory pathogenesis of Parkinson's disease.
Yao L; Ye Y; Mao H; Lu F; He X; Lu G; Zhang S
J Neuroinflammation; 2018 Jan; 15(1):13. PubMed ID: 29329581
[TBL] [Abstract][Full Text] [Related]
18. The MHC class II transactivator modulates seeded alpha-synuclein pathology and dopaminergic neurodegeneration in an in vivo rat model of Parkinson's disease.
Jimenez-Ferrer I; Bäckström F; Dueñas-Rey A; Jewett M; Boza-Serrano A; Luk KC; Deierborg T; Swanberg M
Brain Behav Immun; 2021 Jan; 91():369-382. PubMed ID: 33223048
[TBL] [Abstract][Full Text] [Related]
19. Impaired autophagy in microglia aggravates dopaminergic neurodegeneration by regulating NLRP3 inflammasome activation in experimental models of Parkinson's disease.
Qin Y; Qiu J; Wang P; Liu J; Zhao Y; Jiang F; Lou H
Brain Behav Immun; 2021 Jan; 91():324-338. PubMed ID: 33039664
[TBL] [Abstract][Full Text] [Related]
20. T cell infiltration and upregulation of MHCII in microglia leads to accelerated neuronal loss in an α-synuclein rat model of Parkinson's disease.
Subbarayan MS; Hudson C; Moss LD; Nash KR; Bickford PC
J Neuroinflammation; 2020 Aug; 17(1):242. PubMed ID: 32799878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
